cerus corp. - CERS
CERS
Close Chg Chg %
2.14 0.06 2.80%
Closed Market
2.20
+0.06 (2.80%)
Volume: 1.26M
Last Updated:
Feb 6, 2026, 4:00 PM EDT
Company Overview: cerus corp. - CERS
CERS Key Data
| Open $2.20 | Day Range 2.11 - 2.26 |
| 52 Week Range 1.12 - 2.96 | Market Cap $439.88M |
| Shares Outstanding 192.09M | Public Float 182.98M |
| Beta 1.52 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.08 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.52M |
CERS Performance
| 1 Week | -5.58% | ||
| 1 Month | 6.80% | ||
| 3 Months | 28.65% | ||
| 1 Year | 28.65% | ||
| 5 Years | -70.86% |
CERS Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
4
Full Ratings ➔
About cerus corp. - CERS
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
CERS At a Glance
Cerus Corp.
1220 Concord Avenue
Concord, California 94520
| Phone | 1-925-288-6000 | Revenue | 180.27M | |
| Industry | Medical Specialties | Net Income | -20,918,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 15.286% | |
| Fiscal Year-end | 12 / 2025 | Employees | 281 | |
| View SEC Filings |
CERS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.577 |
| Price to Book Ratio | 5.095 |
| Price to Cash Flow Ratio | 25.02 |
| Enterprise Value to EBITDA | -9.094 |
| Enterprise Value to Sales | 1.679 |
| Total Debt to Enterprise Value | 0.324 |
CERS Efficiency
| Revenue/Employee | 641,530.249 |
| Income Per Employee | -74,441.281 |
| Receivables Turnover | 6.054 |
| Total Asset Turnover | 0.904 |
CERS Liquidity
| Current Ratio | 2.39 |
| Quick Ratio | 1.79 |
| Cash Ratio | 1.265 |
CERS Profitability
| Gross Margin | 54.098 |
| Operating Margin | -19.568 |
| Pretax Margin | -11.514 |
| Net Margin | -11.604 |
| Return on Assets | -10.494 |
| Return on Equity | -38.454 |
| Return on Total Capital | -13.562 |
| Return on Invested Capital | -16.161 |
CERS Capital Structure
| Total Debt to Total Equity | 174.721 |
| Total Debt to Total Capital | 63.599 |
| Total Debt to Total Assets | 48.825 |
| Long-Term Debt to Equity | 136.299 |
| Long-Term Debt to Total Capital | 49.614 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Cerus Corp. - CERS
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 130.86M | 162.05M | 156.37M | 180.27M | |
Sales Growth
| +42.36% | +23.83% | -3.51% | +15.29% | |
Cost of Goods Sold (COGS) incl D&A
| 65.97M | 77.45M | 72.37M | 82.75M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 4.57M | 4.56M | 2.40M | 2.00M | |
Depreciation
| 3.92M | 4.08M | 2.40M | 2.00M | |
Amortization of Intangibles
| - | - | 648.00K | 484.00K | - |
COGS Growth
| +52.17% | +17.40% | -6.57% | +14.34% | |
Gross Income
| 64.88M | 84.59M | 84.00M | 97.52M | |
Gross Income Growth
| +33.61% | +30.38% | -0.70% | +16.10% | |
Gross Profit Margin
| +49.58% | +52.20% | +53.72% | +54.10% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 142.48M | 144.94M | 140.75M | 132.80M | |
Research & Development
| 61.19M | 61.61M | 65.24M | 56.91M | |
Other SG&A
| 81.29M | 83.33M | 75.52M | 75.89M | |
SGA Growth
| +10.51% | +1.73% | -2.89% | -5.65% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | (148.00K) | 570.00K | 3.73M | |
EBIT after Unusual Expense
| (77.45M) | (60.92M) | (60.48M) | (35.28M) | |
Non Operating Income/Expense
| 28.31M | 24.41M | 31.55M | 23.40M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 4.92M | 5.83M | 8.39M | 8.88M | |
Interest Expense Growth
| +31.42% | +18.44% | +43.82% | +5.85% | |
Gross Interest Expense
| 4.92M | 5.83M | 8.39M | 8.88M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (54.06M) | (42.34M) | (37.32M) | (20.76M) | |
Pretax Income Growth
| +9.26% | +21.68% | +11.85% | +44.39% | |
Pretax Margin
| -41.31% | -26.13% | -23.87% | -11.51% | |
Income Tax
| 319.00K | 488.00K | 325.00K | 205.00K | |
Income Tax - Current - Domestic
| - | 5.00K | 36.00K | 70.00K | |
Income Tax - Current - Foreign
| 274.00K | 520.00K | 285.00K | 130.00K | |
Income Tax - Deferred - Domestic
| 45.00K | (37.00K) | 4.00K | 5.00K | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (54.38M) | (42.83M) | (37.65M) | (20.96M) | |
Minority Interest Expense
| (2.00K) | (46.00K) | (158.00K) | (43.00K) | |
Net Income
| (54.37M) | (42.78M) | (37.49M) | (20.92M) | |
Net Income Growth
| +9.16% | +21.32% | +12.37% | +44.20% | |
Net Margin Growth
| -41.55% | -26.40% | -23.98% | -11.60% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (54.37M) | (42.78M) | (37.49M) | (20.92M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (54.37M) | (42.78M) | (37.49M) | (20.92M) | |
EPS (Basic)
| -0.3175 | -0.2423 | -0.208 | -0.1133 | |
EPS (Basic) Growth
| +13.04% | +23.69% | +14.16% | +45.53% | |
Basic Shares Outstanding
| 171.28M | 176.54M | 180.27M | 184.56M | |
EPS (Diluted)
| -0.3175 | -0.2423 | -0.208 | -0.1133 | |
EPS (Diluted) Growth
| +13.04% | +23.69% | +14.16% | +45.53% | |
Diluted Shares Outstanding
| 171.28M | 176.54M | 180.27M | 184.56M | |
EBITDA
| (73.03M) | (55.79M) | (54.35M) | (33.28M) | |
EBITDA Growth
| +3.80% | +23.60% | +2.57% | +38.78% | |
EBITDA Margin
| -55.80% | -34.43% | -34.76% | -18.46% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 4.25 | |
| Number of Ratings | 4 | Current Quarters Estimate | -0.03 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -0.039 | |
| Last Quarter’s Earnings | -0.005 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.079 | Next Fiscal Year Estimate | 0.009 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 3 | 4 | 4 |
| Mean Estimate | -0.03 | -0.01 | -0.04 | 0.01 |
| High Estimates | -0.02 | 0.00 | 0.00 | 0.09 |
| Low Estimate | -0.04 | -0.03 | -0.11 | -0.09 |
| Coefficient of Variance | -31.65 | -173.21 | -118.96 | 868.62 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 3 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Cerus Corp. - CERS
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Cerus Corp. - CERS
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 11, 2025 | Richard J. Benjamin Chief Medical Officer | 760,938 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Chrystal N. Menard Chief Legal Officer | 832,318 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.5 per share | 1,248,477.00 |
| Mar 11, 2025 | Chrystal N. Menard Chief Legal Officer | 859,775 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Chrystal N. Menard Chief Legal Officer | 790,198 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Vivek K. Jayaraman Chief Operating Officer | 1,507,315 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.5 per share | 2,260,972.50 |
| Mar 11, 2025 | Vivek K. Jayaraman Chief Operating Officer | 1,541,314 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Vivek K. Jayaraman Chief Operating Officer | 1,450,828 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Kevin Dennis Green Chief Financial Officer | 935,754 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.5 per share | 1,403,631.00 |
| Mar 11, 2025 | Kevin Dennis Green Chief Financial Officer | 966,902 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Kevin Dennis Green Chief Financial Officer | 886,362 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | William Mariner Greenman President and CEO; Director | 4,309,758 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.5 per share | 6,464,637.00 |
| Mar 11, 2025 | William Mariner Greenman President and CEO; Director | 4,370,742 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | William Mariner Greenman President and CEO; Director | 4,205,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Richard J. Benjamin Chief Medical Officer | 734,799 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.5 per share | 1,102,198.50 |
| Mar 11, 2025 | Richard J. Benjamin Chief Medical Officer | 694,373 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Kevin Dennis Green Chief Financial Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Richard J. Benjamin Chief Medical Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Chrystal N. Menard Chief Legal Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |